Skip to content

Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms

Phase III, Multicenter, Double-Blind Study of the Safety and Efficacy of Bio-E-Gel (Topical Estradiol Gel) Versus Placebo for Treatment of Vasomotor Symptoms and Vulvovaginal Atrophy in Postmenopausal Females

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00391417
Enrollment
431
Registered
2006-10-24
Start date
2003-09-30
Completion date
2005-04-30
Last updated
2006-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hot Flashes

Keywords

hot flush, hot flash, estrogen, vaginal atrophy

Brief summary

The purpose of this study is to determine the efficacy and safety of a topical estradiol gel for the treatment of hot flushes in postmenopausal women.

Detailed description

Estrogens are a group of hormones that play an important role in normal sexual and reproductive development in women. Estrogens serve many functions in the body. They stimulate oocyte maturation and endometrial growth, decrease bone resorption, initiate the development of secondary sex characteristics, maintain reproductive organs and glands, and affect the activity of the central nervous system. At menopause, the decrease in estrogen concentrations is often accompanied by vascular instability (hot flushes and night sweats), a rise in the incidence of heart disease, and an increasing rate of bone loss. Estrogen is available as an oral drug, a transdermal patch, or as a gel or lotion. Transdermal estrogen is preferable as compared to oral, since it avoids the first-pass metabolism in the liver. Since release of the WHI findings, current treatment recommendations are for the lowest effective dose for the shortest period of time to treat postmenopausal symptoms. Comparison: Three doses of a transdermal estradiol gel as compared to placebo for the treatment of vasomotor and vulvovaginal atrophy symptoms in postmenopausal women.

Interventions

Sponsors

BioSante Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Postmenopausal women * serum estradiol level less than or equal to 20 pg per mL * serum FSH greater than 40 mIU per mL

Exclusion criteria

* Pathological cancer findings on screening * abnormal endometrium * serious hepatic, renal or cardiac disease

Design outcomes

Primary

MeasureTime frame
Mean change from baseline in daily hot flush severity.
Mean change from baseline in vulvovaginal atrophy symptoms.
Mean change from baseline in number of daily moderate to severe hot flushes.

Secondary

MeasureTime frame
Percent change from baseline in hot flush severity over time.
Proportion of subjects with fifty to one hundred percent reductions in daily moderate to severe hot flushes.
Proportion of subjects with fifty to one hundred percent reductions in hot flush severity
Mean change from baseline in subject vaginal health self assessment over time.
Mean change from baseline in physician assessment of vaginal atrophy.
Percent change from baseline in daily moderate to severe hot flush rates over time.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026